Chempartner Pharmatech (300149.SZ) announced its performance in the first half of the year, with a net loss of 62.9065 million yuan, an increase of 188.88%.

Chempartner Pharmatech (300149.SZ) released its semi-annual report for 2024, with revenue of 0.465 billion...

According to the semi-annual report for 2024 released by Chempartner Pharmatech (300149.SZ), the company's revenue was 0.465 billion yuan, a decrease of 16.56% year-on-year. The net loss attributable to shareholders of the listed company expanded by 188.88% to 62.9065 million yuan, while the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, expanded by 121.75% to 64.0386 million yuan. The basic loss per share was 0.1263 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

睿智医药(300149.SZ)发布上半年业绩，净亏损6290.65万元，扩大188.88%

Chempartner Pharmatech (300149.SZ) announced its performance in the first half of the year, with a net loss of 62.9065 million yuan, an increase of 188.88%.

Risk Disclaimer

Statement